ClinicalTrials.Veeva

Menu
C

Community Clinical Research, Inc. | Austin, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KarXT
Aripiprazole
Lurasidone
Rapastinel
BI 409306
SEP-363856
Risperidone
LY03004
Armodafinil
Lurasidone HCl

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 89 total trials

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipo...

Enrolling
Bipolar Disorder Type I With Mania
Drug: Valproate
Drug: Lamotrigine

This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD)...

Enrolling
Cognitive Impairment Associated With Schizophrenia (CIAS)
Other: Placebo
Drug: KYN-5356 low dose

The purpose of this study is to evaluate the dose levels, safety, and drug levels of KarXT intramuscular injection in participants with Schizophrenia

Enrolling
Schizophrenia
Drug: KarXT

The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disord...

Enrolling
Bipolar Disorder
Mania
Drug: Placebo
Drug: Xanomeline/Trospium Chloride

Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

Enrolling
Schizophrenia
Drug: SEP-363856
Other: Placebo

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted t...

Enrolling
Bipolar 1 Disorder
Drug: RAP-219
Other: Placebo

Trial sponsors

Otsuka logo
Sumitomo Pharma logo
Karuna Therapeutics logo
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
Allergan logo
C
L
AbbVie logo
Astellas logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems